Cellular pharmacology of fludarabine: molecular determinants of transport and metabolism
Frontiers in Pharmacology · 19.05.2026 · 17
DOI: 10.3389/fphar.2026.1818501 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.05.2026. Verfasst von Mourad Mseddi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cansearch Research Platform for Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology, and Obstetrics, University of Geneva, Geneva…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Fludarabine monophosphate is an antimetabolite and a cornerstone of hematology and oncology treatments, with expanding clinical applications in hematological malignancies, stem cell transplantation conditioning, and chimeric antigen receptor T-cell (CAR-T) therapy. Despite widespread clinical use, there is substantial interpatient pharmacokinetic variability with up to 14.5-fold differences in drug exposure. Suboptimal exposures (both under- and overexposure) correlate directly with both treatment failure and non-relapse mortality, emphasizing the critical need for personalized dosing strategies. The therapeutic efficacy of fludarabine is determined by complex transport and metabolic processes. Cellular uptake is mediated primarily by human equilibrative (hENT1, hENT2) and concentrative nucleoside transporters (hCNT2, hCNT3). Once intracellular, deoxycytidine kinase catalyzes the rate-limiting phosphorylation step, converting fludarabine to its pharmacologically active triphosphate, which inhibits DNA synthesis and repair, ultimately driving cytotoxicity. The elimination mechanisms of fludarabine involve multiple pathways: cytoplasmic 5′-nucleotidase II and CD73-mediated dephosphorylation, while UDP-glucuronosyltransferases (particularly UGT2B17) catalyze glucuronidation-based elimination. The breast cancer resistance protein (BCRP/ ABCG2 ) represents the principal efflux transporter, whereas fludarabine shows minimal interaction with P-glycoprotein and other major multidrug resistance-associated proteins. This review synthesizes current understanding of fludarabine’s cellular pharmacology, providing a framework for identifying biomarkers to guide personalized medicine approaches and to optimize fludarabine therapy and treatment outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cansearch Research Platform for Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology, and Obstetrics, University of Geneva, Geneva, Switzerland.
- Pediatric Onco-Hematology Unit, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, Switzerland.
- Clinical Pharmacology and Toxicology Division, University Hospitals of Geneva, Geneva, Switzerland.
Zitieren
APA
Mseddi, M., Mlakar, V., Gloor, Y., Gonzales, F., Baleydier, F., Daali, Y., & Ansari, M. (2026). Cellular pharmacology of fludarabine: molecular determinants of transport and metabolism. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1818501
Vancouver
Mseddi M, Mlakar V, Gloor Y, Gonzales F, Baleydier F, Daali Y, et al. Cellular pharmacology of fludarabine: molecular determinants of transport and metabolism. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1818501
BibTeX
@article{Mseddi2026,
author = {Mseddi, Mourad and Mlakar, Vid and Gloor, Yvonne and Gonzales, Fanny and Baleydier, Frederic and Daali, Youssef and Ansari, Marc},
title = {Cellular pharmacology of fludarabine: molecular determinants of transport and metabolism},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1818501}
}
EUVIMED